Answers are grounded in this paper and cite their sources.
Brain tumour related epilepsy (BTRE) occurs in up to 80% of patients with tumours, most commonly in those with lower grade (WHO Grade I and II) lesions. The association between presence of the IDH 1mutation and refractory seizures is unclear. Despite the availability of multiple anti-seizure medications, up to a third of patients experience refractory seizures. Cenobamate (CNB) was licenced in Dec 2021 as an adjunctive treatment for focal epilepsy. Evidence for its efficacy for BTRE is limited. To investigate the efficacy (≥ 50% seizure reduction) of adjunctive CNB for BTRE. To investigate a possible association between presence of the IDH1 mutation and responsiveness to CNB. This was a retrospective single centre cohort study of patients prescribed CNB for BTRE by an epilepsy specialist between Jan 2022 and Jan 2026. Seizure frequency was assessed by case note review. 23 patients (13 males) were included, average duration of follow up was 17.6 months. Patients had tried a minimum of 2 antiseizure medications. 16 patients (70%) responded to CNB, of whom 6 (37.5%) achieved ≥ 90% seizure freedom. All non-responders had low grade lesions, there were significantly more responders with high grade lesions. 7 non-responders discontinued CNB by last follow up due to self-limiting sedative side effects. There was no correlation between presence of an IDH1 mutation (n= 5) and response to CNB. Cenobamate is a potentially effective antiseizure medication for refractory BTRE. It can be associated with sedative side effects; titration needs to be optimised, especially in those who have previously undergone chemo/ radiotherapy.
No takes yet. Share an insight, caveat, or question.
Maha et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: